Episcleral clearance of sodium fluorescein from a bioerodible sub-tenon's implant in the rat

Experimental Eye Research

Volumn 90, Issue 4, 2010, Pages 501-506

  Chan, Jessica E ^a   Pridgen, Tiffany A ^b   Csaky, Karl G ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Animal model; Drug delivery; Episcleral lymphatics; Sodium fluorescein

Indexed keywords

FLUORESCEIN SODIUM; INDOCYANINE GREEN;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; BIODEGRADABLE IMPLANT; CHOROID; CONJUNCTIVA; CONTROLLED STUDY; DIFFUSION; DIODE LASER; DOSE RESPONSE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG RELEASE; DRUG SOLUBILITY; DRUG TISSUE LEVEL; FEMALE; FLUORESCENCE ANALYSIS; FLUOROMETER; IN VITRO STUDY; IN VIVO STUDY; KINETICS; LOW DRUG DOSE; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SCLERA; SOLUBILIZATION; STAINING; THEORY VALIDATION; TIME;

ABSORBABLE IMPLANTS; ANIMALS; CHOROID; CONJUNCTIVA; CONNECTIVE TISSUE; DRUG IMPLANTS; FASCIA; FEMALE; FLUORESCEIN; LASER COAGULATION; RATS; RATS, SPRAGUE-DAWLEY; SCLERA; SPECTROMETRY, FLUORESCENCE;

EID: 77950023355     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2010.01.001     Document Type: Article

References (25)

1. Ahmed I., Gokhale R.D., et al. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J. Pharm. Sci. 1987, 76(8):583-586.
2. Amrite A.C., Edelhauser H.F., et al. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest. Ophthalmol. Vis. Sci. 2008, 49(1):320-332.
3. Amrite A.C., Edelhauser H.F., et al. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol. Vis. 2008, 14:150-160.
4. Amrite A.C., Kompella U.B. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J. Pharm. Pharmacol. 2005, 57(12):1555-1563.
5. Ayalasomayajula S.P., Kompella U.B. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur. J. Pharmacol. 2005, 511(2-3):191-198.
6. Balachandran R.K., Barocas V.H. Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow. Pharm. Res. 2008, 25(11):2685-2696.
7. Bhutto I.A., Amemiya T. Microvascular architecture of the rat choroid: corrosion cast study. Anat. Rec. 2001, 264(1):63-71.
8. Bill A. Movement of albumin and dextran through the sclera. Arch. Ophthalmol. 1965, 74:248-252.
9. Bill A. Circulation in the Eye 1984, vol. IV. Am. Physiol. Soc, Bethesda, MD, pp. 1001-1034.
10. Camelo S., Kezic J., et al. Antigen from the anterior chamber of the eye travels in a soluble form to secondary lymphoid organs via lymphatic and vascular routes. Invest. Ophthalmol. Vis. Sci. 2006, 47(3):1039-1046.
11. Edelhauser H.F., Maren T.H. Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors. Arch. Ophthalmol. 1988, 106(8):1110-1115.
12. Furrer E., Berdugo M., et al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-{alpha} single-chain antibody, upon topical administration to the rabbit eye. Invest. Ophthalmol. Vis. Sci. 2009, 50(2):771-778.
13. Geroski D.H., Edelhauser H.F. Transscleral drug delivery for posterior segment disease. Adv. Drug Deliv. Rev. 2001, 52(1):37-48.
14. Ghate D., Brooks W., et al. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest. Ophthalmol. Vis. Sci. 2007, 48(5):2230-2237.
15. Hoffmann F., Zhang E.P., et al. Contribution of lymphatic drainage system in corneal allograft rejection in mice. Graefes Arch. Clin. Exp. Ophthalmol. 2001, 239(11):850-858.
16. Jaffe G.J., Martin D., et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006, 113(6):1020-1027.
17. Jager R.D., Aiello L.P., et al. Risks of intravitreous injection: a comprehensive review. Retina 2004, 24(5):676-698.
18. Karol M.D., Veng-Pedersen P., et al. Diffusion and flow transfer of theophylline across the blood-brain barrier: pharmacokinetic analysis. J. Pharmacokinet. Biopharm. 1983, 11(3):273-287.
19. Kim H., Robinson M.R., et al. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest. Ophthalmol. Vis. Sci. 2004, 45(8):2722-2731.
20. Lee S.J., Kim E.S., et al. Pharmacokinetics of intraocular drug delivery of oregon green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes. Invest. Ophthalmol. Vis. Sci. 2008, 49(10):4506-4514.
21. Maurice D.M., Polgar J. Diffusion across the sclera. Exp. Eye Res. 1977, 25(6):577-582.
22. Musch D.C., Martin D.F., et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N. Engl. J. Med. 1997, 337(2):83-90. The Ganciclovir Implant Study Group.
23. Pfister M., Zhang L., et al. Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin. Antimicrob. Agents Chemother. 2003, 47(1):138-143.
24. Ranta V.P., Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv. Drug Deliv. Rev. 2006, 58(11):1164-1181.
25. Robinson M.R., Lee S.S., et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp. Eye Res. 2006, 82(3):479-487.